Assembly Biosciences (ASMB) vs Contineum Therapeutics (CTNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Contineum Therapeutics (CTNM) has outperformed Assembly Biosciences (ASMB) over the past year, gaining 11.8% versus a loss of 3.8%. Contineum Therapeutics is the larger company by market cap ($478.9 million vs $467.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASMB | CTNM |
|---|---|---|
| Share price | $22.95 | $12.73 |
| Market cap | $467.28M | $478.92M |
| 1-day change | +3.47% | +0.63% |
| YTD return | -32.52% | +11.37% |
| 1-year return | -3.81% | +11.76% |
| 5-year return | -41.33% | — |
| P/E ratio (TTM) | 22.07 | — |
| EPS (TTM) | $1.04 | $-1.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $39.71 | $17.79 |
| 52-week low | $21.80 | $8.60 |
| Distance from 52-week high | -42.21% | -28.42% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +126.58% | +76.20% |
| Average volume | 277.22K | 499.57K |
| Shares outstanding | 20.36M | 32.96M |
| Employees | 73 | 51 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTNM has outperformed ASMB by 15.6 percentage points over the past year.
About Assembly Biosciences
ASMB stock →Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Healthcare · Biotechnology · 73 employees
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Healthcare · Biotechnology · 51 employees
ASMB vs CTNM FAQ
Which is bigger, Assembly Biosciences or Contineum Therapeutics?
Contineum Therapeutics (CTNM) is larger, with a market capitalization of $478.92M compared with $467.28M for Assembly Biosciences (ASMB).
Which stock has performed better over the past year, ASMB or CTNM?
CTNM returned +11.76% over the past 12 months, compared with -3.81% for ASMB (price return, excluding dividends). Past performance does not predict future results.
Are Assembly Biosciences and Contineum Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.